C. Mayo

发表

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

M. Taron, S. Benlloch, T. Moran, 2010 .

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

V. Guillem, L. Paz-Ares, R. Rosell, 2010, European Respiratory Journal.

First Description of an Enteric-Type Adenocarcinoma with a High-Grade Neuroendocrine Component of the Lung

M. Esteller, M. Teresa, E. Musulen, 2021 .

EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.

E. Felip, R. Rosell, M. Taron, 2012 .

Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)

R. Rosell, M. Taron, M. Provencio, 2008 .

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

C. García-Girón, R. Rosell, M. Taron, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS)

R. Rosell, M. Taron, N. Reguart, 2007 .

KRAS mutations in lung cancer.

Carlota Costa, Rafael Rosell, Miguel Angel Molina-Vila, 2013, Clinical lung cancer.

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion.

R. Rosell, M. Taron, C. Camps, 2010 .

EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study.

Bauke Ylstra, Daoud Sie, Erik Thunnissen, 2013, Lung cancer.

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response

R. Rosell, M. Santarpia, M. Fernández-Figueras, 2016, Oncotarget.

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients

R. Rosell, M. Taron, M. Santarpia, 2011, Journal of Translational Medicine.

Screening for epidermal growth factor receptor mutations in lung cancer.

Mariano Provencio, Miguel Angel Molina, Bartomeu Massuti, 2009, The New England journal of medicine.

Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial

B. Klughammer, M. Taron, S. Y. Cajal, 2014, PloS one.

Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.

Carlota Costa, Rafael Rosell, R. Rosell, 2012, Pharmacogenomics.

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

Miguel Angel Molina, Bartomeu Massuti, Carlos Camps, 2010, Journal of Translational Medicine.

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

J. Mate, C. Sawyers, A. Ariza, 2011, Clinical Cancer Research.

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells

J. Mate, R. Rosell, M. Taron, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations

R. Rosell, B. Massuti, J. Sánchez, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

In vitro differentiation of HT‐29 M6 mucus‐secreting colon cancer cells involves a trychostatin A and p27KIP1‐inducible transcriptional program of gene expression

J. Lloreta, F. Real, X. Mayol, 2007, Journal of cellular physiology.

Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial.

M. Taron, B. Massuti, C. Camps, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors.

Carlota Costa, Santiago Viteri, Rafael Rosell, 2013, Translational lung cancer research.

Identification of AEG-1 and BARD1 as predictors of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multiple target profiling.

M. Taron, M. Santarpia, S. Benlloch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methotrexate resistance in vitro is achieved by a dynamic selectionprocess of tumor cell variants emerging during treatment

S. Serrano, F. Real, F. Solé, 2006, International journal of cancer.

Cyclin D1 negatively regulates the expression of differentiation genes in HT-29 M6 mucus-secreting colon cancer cells.

X. Mayol, C. Mayo, 2009, Cancer letters.

Screening for epidermal growth factor receptor mutations in lung cancer.

L. Paz-Ares, R. Rosell, M. Taron, 2009, The New England journal of medicine.

V. Guillem, L. Paz-Ares, R. Rosell, 2010 .